Crown Marketing Takes Aim at Diabetes Medication

Crown Marketing Takes Aim at Diabetes Medication 
CHAPEL HILL, NC -- (Marketwire) -- 01/31/13 --  Crown Marketing
(OTCQB: CWNM) is pleased to announce that it has achieved positive
in-vitro testing results of the most widely prescribed Diabetes drug
commonly known as Metformin. As the accompanying image indicates,
Crown's Controlled Drug Delivery Device (CDDT) is less than half the
size of the 500mg dosage tablet, and may reduce and ameliorate many
of the gastrointestinal side effects of Metformin. The most common
adverse effects of Metformin are gastrointestinal upset including
diarrhea, cramps, nausea and vomiting. Crown believes it can
significantly reduce or eliminate these effects with its patented
technology. 
Patients also have issues about the taste and odor associated with
the medication. Common complaints are that it "smells fishy" and can
leave a metallic taste in the mouth. This is critical because it
impacts patient compliance -- if it tastes or smells bad, patients
oftentimes will not take the medication as directed. Crown's CDDT can
overcome these issues due to its novel, diffusion based design and
its impermable coating. According to IMS figures, the total market
sales for all forms of Metformin were $1.6 billion, with sales of
Metformin extended-release formulation alone accounting for over $460
million last year. 
About The Company: 
Crown's Controlled Drug Delivery Technology (CDDT) is a novel
controlled-release technology, harnessing the principles of diffusion
through precise mathematical formulas. 
The spectrum and reliability of pharmacokinetic profiles achievable
with this technology is superior to currently marketed formulations.
Its simple design allows for a high level of flexibility in matching
chronotherapeutic requirements. Cost-efficiencies in the commercial
manufacturing process, when compared to other drug delivery
technologies, may constitute its most important competitive
advantage. 
The objective of intelligent drug delivery design amounts to
maximizing the percent of the time drug plasma levels are within the
therapeutic range and avoiding patient exposure to potentially toxic
(High) or sub-therapeutic (Low) levels.  
Crown's cost-effective application of controlled delivery
technologies will play a major role in the expansion of t
he
pharmaceutical, OTC and nutraceuticals industry through our ability
to improve on the performance of immediate release products in a
manner tangible to manufacturers and consumers.  
More information can be found at: www.crowncddt.com 
This release may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements contained in this release that are not historical facts
may be deemed to be forward-looking statements. Investors are
cautioned that forward-looking statements are inherently uncertain.
Actual performance and results may differ materially from that
projected or suggested herein due to certain risks and uncertainties
including, without limitation, ability to obtain financing and
regulatory and shareholder approvals for anticipated actions. 
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2216168 
Contact: 
Charles Van Der Ross
347-491-0565 
 
 
Press spacebar to pause and continue. Press esc to stop.